Video Content as Warning-Letter Evidence

Updated August 25, 2026

In warning letter 695156-12102024, dated December 10, 2024, FDA quoted a video from Prime Peptides' own YouTube channel — both the text shown on screen and the words spoken in it — as evidence of intended use. The video sat on a platform the agency tied to the storefront by a purchase-direction finding.

The letter behind the record

The letter went to Prime Vitality, Inc. dba Prime Peptides of Santa Barbara, California, operator of primepeptides.co, as one of four letters issued to research-peptide sellers on December 10, 2024. The agency's site review took place in October 2024, roughly two months before the letters issued. Alongside the website, the letter names three social platforms — Facebook, Instagram, and YouTube — and applies the same attribution sentence to each: the property "directs consumers to your … website to purchase your products." That sentence is what makes a platform account part of the seller's record; once attributed, its contents are read under 21 CFR 201.128, the intended-use regulation. The full letter is documented at this index's Prime Peptides letter record, and the four-letter action at the December 10, 2024 batch page.

The video citation, as recorded

Spoken narration entered the record

What separates this citation from an ordinary screenshot of marketing copy is the second line of the "Material quoted" row. The agency did not stop at what appeared in writing below or within the video. The words spoken in it were transcribed and set into the letter with the same evidentiary standing as anything typed on the website. Two consequences follow, and both belong in a record of the method. First, a video is a labeling surface: under the intended-use reading, footage a seller publishes about its products is examined like a product page. Second, transcription is part of the review — nothing about the spoken form of a statement kept it out of the letter.

One method among several in the same letter

The video citation is one of several evidence categories the Prime Peptides letter documents. The same letter quoted outcome-bearing customer reviews the seller had reposted, recorded at the review-amplification page, and a post from the company's on-domain blog, recorded at the blog-as-labeling page. Read together, the three show a single review sweeping every surface the seller published on, with the video record establishing that the sweep covered sound as well as text.

Mechanics and current status

The letter followed the mechanics common to the batch: delivery by email, a demanded response within 15 working days, and an escalation warning naming "seizure and injunction." FDA posted it publicly on December 17, 2024, one week after issuance. As of this page's dateline, no close-out letter or follow-on action has been found for this recipient; the outcome of the letter is unknown, and this index records it as unknown. The general anatomy of these documents is at the warning-letter explainer; the recipient's entity record is held in the vendor index.

Sources

1. FDA Warning Letter, Prime Vitality, Inc. dba Prime Peptides, 695156-12102024. fda.gov
2. FDA Warning Letters index. fda.gov
3. FDA Roundup, December 17, 2024. fda.gov

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.